These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 31660579)
1. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Granberg KJ; Raita A; Lehtinen B; Tiihonen AM; Kesseli J; Annala M; Rodriguez-Martinez A; Nordfors K; Zhang W; Visakorpi T; Nykter M; Haapasalo H Histol Histopathol; 2020 Jul; 35(7):673-680. PubMed ID: 31660579 [TBL] [Abstract][Full Text] [Related]
2. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. Lehtinen B; Raita A; Kesseli J; Annala M; Nordfors K; Yli-Harja O; Zhang W; Visakorpi T; Nykter M; Haapasalo H; Granberg KJ BMC Cancer; 2017 May; 17(1):310. PubMed ID: 28468611 [TBL] [Abstract][Full Text] [Related]
3. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477 [TBL] [Abstract][Full Text] [Related]
4. P53 expression in choroid plexus neoplasms: an immunohistochemical study. Jay V; Ho M; Chan F; Malkin D Arch Pathol Lab Med; 1996 Nov; 120(11):1061-5. PubMed ID: 12049110 [TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer. Starska K; Forma E; Lewy-Trenda I; Stasikowska-Kanicka O; Skóra M; Bryś M Cell Oncol (Dordr); 2018 Jun; 41(3):253-268. PubMed ID: 29299828 [TBL] [Abstract][Full Text] [Related]
6. Erythropoietin receptor expression in normal and neoplastic choroid plexus. Beschorner R; Psaras T; Meyermann R; Bremer J; Schmidt T; Mittelbronn M; Schittenhelm J Clin Neuropathol; 2011; 30(1):33-40. PubMed ID: 21176716 [TBL] [Abstract][Full Text] [Related]
7. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. Tabori U; Shlien A; Baskin B; Levitt S; Ray P; Alon N; Hawkins C; Bouffet E; Pienkowska M; Lafay-Cousin L; Gozali A; Zhukova N; Shane L; Gonzalez I; Finlay J; Malkin D J Clin Oncol; 2010 Apr; 28(12):1995-2001. PubMed ID: 20308654 [TBL] [Abstract][Full Text] [Related]
8. Loss of TP53 expression in immortalized choroid plexus epithelial cells results in increased resistance to anticancer agents. Krzyzankova M; Mertsch S; Koos B; Jeibmann A; Kruse A; Kordes U; Frühwald MC; Wolff JE; Paulus W; Hasselblatt M J Neurooncol; 2012 Sep; 109(3):449-55. PubMed ID: 22763759 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive identification of Gu W; Yang J; Wang Y; Xu J; Wang X; Du F; Hu X; Guo H; Song C; Tao R; Zhang X Am J Cancer Res; 2021; 11(8):3893-3906. PubMed ID: 34522456 [TBL] [Abstract][Full Text] [Related]
11. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843 [TBL] [Abstract][Full Text] [Related]
12. DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. Pienkowska M; Choufani S; Turinsky AL; Guha T; Merino DM; Novokmet A; Brudno M; Weksberg R; Shlien A; Hawkins C; Bouffet E; Tabori U; Gilbertson RJ; Finlay JL; Jabado N; Thomas C; Sill M; Capper D; Hasselblatt M; Malkin D Clin Epigenetics; 2019 Aug; 11(1):117. PubMed ID: 31409384 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel diagnostic markers for choroid plexus tumors: a microarray-based approach. Hasselblatt M; Böhm C; Tatenhorst L; Dinh V; Newrzella D; Keyvani K; Jeibmann A; Buerger H; Rickert CH; Paulus W Am J Surg Pathol; 2006 Jan; 30(1):66-74. PubMed ID: 16330944 [TBL] [Abstract][Full Text] [Related]